UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of non-metastatic castration-resistant prostate cancer

Urologie pro praxi, 2021-01, Vol.21 (4), p.156-159

Kocák, Ivo

2021

Volltextzugriff (PDF)

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

The Lancet (British edition), 2010-10, Vol.376 (9747), p.1147-1154

2010

Volltextzugriff (PDF)

Significant Anti‑tumor Effectiveness of Imatinib in C‑ kit Negative Gastrointestinal Stromal Tumor – Case Report

Klinická onkologie, 2014-02, Vol.27 (1), p.52-55

2014

Volltextzugriff (PDF)

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients

Current oncology (Toronto), 2022-06, Vol.29 (6), p.4138-4147

2022

Volltextzugriff (PDF)

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

The lancet oncology, 2018-07, Vol.19 (7), p.975-986

2018

Volltextzugriff (PDF)

Oligometastatic Prostate Cancer

Klinická onkologie, 2019, Vol.32 (2)

2019

Volltextzugriff (PDF)

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

The New England journal of medicine, 2019-12, Vol.381 (26), p.2506-2518

2019

Volltextzugriff (PDF)

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

The lancet oncology, 2022-10, Vol.23 (10), p.1297-1307

2022

Volltextzugriff (PDF)

Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.234-234

2019

Volltextzugriff (PDF)

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5003-5003

2018

Volltextzugriff (PDF)

Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases

Klinická onkologie, 2013, Vol.26 (2), p.114-123

2013

Volltextzugriff (PDF)

Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute

Klinická onkologie, 2009, Vol.22 (1), p.27

2009

Volltextzugriff (PDF)

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry

Anticancer research, 2015-06, Vol.35 (6), p.3455

2015

Volltextzugriff (PDF)

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5017-5017

2016

Volltextzugriff (PDF)

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

The lancet oncology, 2018-04, Vol.19 (4), p.510-520

2018

Volltextzugriff (PDF)

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

The lancet oncology, 2018-04, Vol.19 (4), p.510

2018

Volltextzugriff (PDF)

Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma

Journal of Immunology, 2007-06, Vol.178 (11), p.6789-6795

2007

Volltextzugriff (PDF)

First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS4696-TPS4696

2012

Volltextzugriff (PDF)

Prognostic factors for survival in the phase III TROPIC trial

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.102-102

2012

Volltextzugriff (PDF)

F.129. Identification and In Vitro Expansion of Melanoma-Specific T-Cells

Clinical immunology (Orlando, Fla.), 2006, Vol.119, p.S96-S96

2006

Volltextzugriff (PDF)

Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients

Oncology reports, 2001-05, Vol.8 (3), p.685

2001

Volltextzugriff (PDF)

Salmonella enterica Serovar Enteritidis Liver Abscess after Blunt Abdominal Trauma

Balkan medical journal, 2017-09, Vol.34 (5), p.469-472

2017

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(22)

Sprache

Englisch
(21)
Tschechisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Male
(10)
Middle Aged
(9)
Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Aged
(7)
Adult
(6)
Female
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Cancer Therapies
(4)
Disease-Free Survival
(4)
Oncology
(4)
Patients
(4)
Prostate Cancer
(4)
Treatment Outcome
(4)
Androgens
(3)
Castration
(3)
Chemotherapy
(3)
Double-Blind Studies
(3)
General & Internal Medicine
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment of non-metastatic castration-resistant prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Significant Anti‑tumor Effectiveness of Imatinib in C‑ kit Negative Gastrointestinal Stromal Tumor – Case Report

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Oligometastatic Prostate Cancer

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial

Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases

Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study)

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma

First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel

Prognostic factors for survival in the phase III TROPIC trial

F.129. Identification and In Vitro Expansion of Melanoma-Specific T-Cells

Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients

Salmonella enterica Serovar Enteritidis Liver Abscess after Blunt Abdominal Trauma

Suchergebnisse filtern